ROS1在肺腺癌组织中的表达及临床意义

ROS1 expression in pulmonary adenocarcinoma and its clinical significance

目的探讨肺腺癌组织中ROS1蛋白的表达及其临床意义。方法应用免疫组织化学染色法(immunohistochemical,IHC)检测332例肺腺癌组织和55例相应癌旁正常肺组织中ROS1蛋白的表达,分析ROS1蛋白表达与临床病理特征、表皮生长因子受体(epidermal growth factor receptor,EGFR)、间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)和患者术后复发转移的关系。结果 ROS1蛋白在肺腺癌组织和相应癌旁正常肺组织中的阳性表达率分别为6%(20/332)和0,两组比较差异有统计学意义(P<0.05);ROS1蛋白阳性表达在不同年龄、性别肺腺癌患者中的差异无统计学意义(P>0.05);与吸烟史及TNM分期有关(P<0.05),ROS1蛋白阳性组和阴性组中位无病生存期分别为19个月和42个月,差异有统计学意义(P<0.05),1年复发率分别为30%和13.5%,差异有统计学意义(P<0.05)。结论 ROS1蛋白在肺腺癌组织中低表达,ROS1对肺腺癌患者术后生存期和复发转移有一定影响,检测肺腺癌患者ROS1蛋白对指导个体化治疗有重要意义。

Objective To detect the expression of ROS1 protein and its potential clinical significance in patients with pulmonary adenocarcinoma. Methods Formalin-fixed,paraffin-embedded tissue microarrays prepared from 332 patients with pulmonary adenocarcinoma and 55 samples of adjacent normal lung tissue were analyzed for ROS1 expression using immunohistochemistry. Possible relationships were analyzed between ROS1 expression and clinicopathologic features or EGFR/ALK protein expression, as well as between protein expression and postoperative recurrence. Results The rate of ROS1 expression was 6% in pulmonary adenocarcinoma tissues and 0 in adjacent normal lung tissue（P〈0.05）. ROS1 expression did not correlate with age or gender, but it did correlate significantly with smoking history and clinical stage（P〈0.05）. Disease-free survival was 42 months in ROS1-negative patients and 19 months in ROS1-positive patients（P〈0.05）. Rate of recurrence at 1 year was 30% in ROS1-negative patients and 13.5% in ROS1-positive patients（P〈0.05）. Conclusion Expression of ROS1 protein is low in pulmonary adenocarcinoma. ROS1 may be a prognostic factor that predicts risk of recurrence and metastasis of lung adenocarcinoma. Screening for ROS1 expression may help guide clinical treatment.